Skip to main content
    • Mounjaro
    • Wegovy

    Mounjaro Eye Side Effects: The FDA Warning and Your Eyesight

    The FDA has ordered an eye warning for Mounjaro and every GLP-1 medicine. What NAION is, how rare it is, what UK leaflets say and when to get help.

    Jimah Alsaai MPharmJimah Alsaai MPharmSuperintendent Pharmacist
    GPhC 2232652
    Reviewed November 2026
    10 min read

    Start your free consultation with a GPhC-registered pharmacist.

    Begin consultation

    Short answer: on 9 November 2026 the US medicines regulator, the FDA, told the makers of every GLP-1 medicine, Mounjaro (tirzepatide) included, to add a warning about NAION, a rare eye condition that causes a sudden, painless loss of vision, usually in one eye.

    It is rare with or without the medicine. In the FDA's analysis of 126 clinical trials there were about 6 cases a year for every 100,000 people on a GLP-1 medicine, against about 4 for people on a placebo or another diabetes medicine.

    The FDA calls it a potential increased risk. Its figures show more cases in people taking these medicines; they do not prove the medicines were the cause.

    In the UK, the product information for Wegovy already lists NAION as very rare, and Mounjaro's does not list it as of November 2026. Whichever you take, a sudden loss of vision, or of part of your field of vision, needs eye casualty or A&E the same day.

    This guide sets out what the FDA announced, what it means in the UK, the figures behind it and what to do if your eyesight changes, as of November 2026.

    What has the FDA said about Mounjaro and your eyes?

    The FDA said on 9 November 2026 that it is requiring the makers of all GLP-1 medicines to add information about a potential increased risk of NAION to their US prescribing information.

    Its list names tirzepatide (Mounjaro, and Zepbound in the US), semaglutide (Wegovy, Ozempic and Rybelsus) and orforglipron (Foundayo), with the older medicines liraglutide, dulaglutide, exenatide and lixisenatide.

    It goes in the Warnings and Precautions section of that document, which prescribers and pharmacists work from. The notice does not describe it as a boxed warning.

    The FDA regulates medicines in the United States. UK packs and leaflets are regulated by the MHRA, so the announcement changes nothing in the UK by itself.

    A Mounjaro KwikPen, 12.5mg
    A Mounjaro KwikPen. The FDA's warning covers every GLP-1 medicine, tirzepatide included, at every strength.

    How the warning came about

    1. July 2024

      A study from one US eye hospital reports more NAION in people prescribed semaglutide. The FDA says it prompted its review.

    2. June 2025

      The European Medicines Agency concludes that NAION is a very rare side effect of semaglutide.

    3. February 2026

      The MHRA issues a UK Drug Safety Update on semaglutide and says it is reviewing other GLP-1 medicines.

    4. November 2026

      The FDA requires a warning for every GLP-1 medicine in the US, tirzepatide included.

    What is NAION?

    NAION (non-arteritic anterior ischaemic optic neuropathy) is a sudden loss of vision caused by reduced blood flow to the front of the optic nerve. It usually affects one eye, and it is painless.

    The FDA lists these symptoms:

    • a sudden, painless loss of vision in one eye, which you may notice on waking
    • blurred or missing parts of your vision, such as blind spots or tunnel vision
    • colours looking distorted
    • blurry or hazy central vision

    The FDA says to contact a healthcare professional straight away with any of them. A sudden loss of vision means eye casualty or A&E: the steps further down say what to do.

    The loss of vision can be permanent. The FDA says that once NAION has happened in one eye, the risk in the other eye is higher.

    NAION also happens in people who have never taken a GLP-1 medicine. Between them, the FDA and the MHRA name diabetes, high blood pressure, high cholesterol, smoking, sleep apnoea, anaemia and kidney disease as risk factors.

    Several of those are common in people who are prescribed these medicines, which is one reason the link is hard to study.

    How common is NAION with Mounjaro and other GLP-1 medicines?

    It is rare. The chart shows the FDA's figures from 126 clinical trials of GLP-1 medicines taken together. Its notice gives no separate figure for Mounjaro.

    NAION in clinical trials of GLP-1 medicinesCases a year for every 100,000 people
    • Taking a GLP-1 medicine6.4
    • Taking a placebo or another diabetes medicine3.8
    • Adults over 50 in general, across published studies2.3 to 10.2
    FDA Drug Safety Communication, 9 November 2026: its analysis of 126 randomised trials of GLP-1 medicines, 134,253 people. The range for adults over 50 is the FDA's summary of published studies of the general population, and the lighter part of that bar is the range. The FDA does not give the ages of the people in the trials, so that range is context, not a like-for-like comparison.

    Those rates come from 15 probable cases among 134,253 people: 10 in people on a GLP-1 medicine and 5 in people on a placebo. With so few cases, the gap between the bars is an estimate, not a precise measure.

    The FDA also studied health data for US adults with type 2 diabetes who started a new medicine between 2019 and 2024.

    NAION in US adults with type 2 diabetes, by the medicine they startedCases a year for every 100,000 people
    • A GLP-1 medicine30 to 32
    • An SGLT-2 inhibitor31
    • A DPP-4 inhibitor26
    FDA Sentinel study, in the same notice. The lighter part of the first bar is the range the FDA gives.

    The bars are simple rates. When the FDA compared the groups directly, it found an increase against DPP-4 inhibitors and no statistically significant increase against SGLT-2 inhibitors. Both results are in the chart of studies below.

    The rates are higher for every group than in the trials. The FDA does not say why, and the two sets of figures were gathered in different ways, so they should not be compared.

    Everyone in this study had type 2 diabetes, where the MHRA puts the background rate at 11.4 to 82 cases a year for every 100,000 people.

    For semaglutide, the UK and European regulators describe the risk another way: about twice as high in adults with type 2 diabetes, or about one extra case for every 10,000 people treated for a year.

    By 1 August 2025 the MHRA had received three Yellow Card reports suggestive of NAION with semaglutide, against about 10.2 million packs dispensed in five years. A report does not prove the medicine was the cause.

    Can Mounjaro cause blindness?

    It is not known for certain, and if it can, it is rare. The FDA's words are a "potential increased risk", for GLP-1 medicines as a group, of NAION, which can cause permanent loss of vision in the eye it affects.

    Blindness is not listed as a side effect in Mounjaro's UK product information.

    The FDA acted on its trial figures, its own study of health data, and published studies that it says "consistently reported an increased risk" in people with type 2 diabetes starting a GLP-1 medicine.

    It has not said that these medicines cause NAION, and its review of animal studies did not identify how one could lead to it. It does say cases have been reported with every GLP-1 medicine on the market.

    What the studies found

    The first study, from one US eye hospital in 2024, found a large increase with semaglutide. It studied people already referred to a specialist eye clinic, so it could not show how common NAION is. Larger studies since have found smaller increases, and some found no clear difference.

    NAION and GLP-1 medicines: what seven studies foundEach row is one comparison, and some studies appear more than once. The figure is how many times the rate of NAION in people on the medicine was the rate in the comparison group: 1 means the same, 2 means twice the rate. The line through each dot is the range the true figure is likely to lie in.
    The study found more cases with the medicineThe study could not tell the groups apart
    People with type 2 diabetes
    • Hathaway and colleagues, 20244.28 (1.62 to 11.29)
      One US eye hospital, 710 people. Semaglutide against other diabetes medicines.
    • Grauslund and colleagues, 20242.19 (1.54 to 3.12)
      Denmark, 424,152 people. Semaglutide against no semaglutide.
    • Simonsen and colleagues, 20252.81 (1.67 to 4.75)
      Denmark and Norway, 61,377 people starting semaglutide. Against SGLT-2 inhibitors.
    • Cai and colleagues, 20251.32 (1.14 to 1.54)
      14 health databases covering 37.1 million people with type 2 diabetes, 810,390 of them starting semaglutide. Time on semaglutide against time off it, in the same people. Its comparisons with three other diabetes medicines mostly found no clear difference.
    • Chou and colleagues, 20251.51 (0.71 to 3.25)
      Health records from 21 countries, 37,314 people with type 2 diabetes and no obesity, after 3 years. Semaglutide against other medicines.
    • Chou and colleagues, 20251.19 (0.78 to 1.82)
      The same study, 130,216 people with type 2 diabetes and obesity, after 3 years.
    • Wang and colleagues, 20251.76 (1.01 to 3.07)
      US health records, 159,398 people. Semaglutide or tirzepatide against other diabetes medicines, older GLP-1 medicines among them.
    • FDA Sentinel study, 20261.19 (0.91 to 1.54)
      US health data, adults starting a medicine between 2019 and 2024. GLP-1 medicines against SGLT-2 inhibitors.
    • FDA Sentinel study, 20261.43 (1.02 to 2.01)
      The same study. GLP-1 medicines against DPP-4 inhibitors.
    People with overweight or obesity
    • Hathaway and colleagues, 20247.64 (2.21 to 26.36)
      The same eye hospital, 979 people. Semaglutide against other weight-loss medicines.
    • Chou and colleagues, 20250.72 (0.24 to 2.16)
      Health records from 21 countries, 129,690 people with obesity and no type 2 diabetes, after 3 years. Semaglutide against other medicines.
    Hazard ratios with 95% confidence intervals (for Cai, a rate ratio), as each paper's abstract on PubMed and the FDA's notice of 9 November 2026 report them. These are seven of the published studies, not all of them: another large study of health records (Abbass and colleagues, 2025) found no increase. All are studies of health records, not trials, so none can show cause and effect. The references are in the sources at the end of this guide.

    Nearly all of this research is on semaglutide in people with type 2 diabetes. For tirzepatide, and for people taking these medicines for weight management without diabetes, there is far less to go on.

    One study counted tirzepatide together with semaglutide: 35 cases of NAION among 79,699 people over two years, against 19 among the same number on other diabetes medicines.

    The few studies of tirzepatide on its own draw on health records and on reports of suspected side effects, and none can show whether the risk differs between medicines. The FDA applied the same warning to every GLP-1 medicine.

    Is the warning in the UK leaflets for Mounjaro and Wegovy?

    For Wegovy, yes. For Mounjaro, not as of 11 November 2026.

    MedicineWhat its UK product information says about NAIONText last revised
    Mounjaro (tirzepatide)Not listed. Its one eye warning is about diabetic retinopathy.29 August 2026
    Wegovy injection (semaglutide)A warning, and a listed side effect: very rare, up to 1 in 10,000 people. Treatment is stopped if NAION is confirmed.September 2026
    Wegovy tablets (semaglutide)The same warning as the injection.June 2026
    Foundayo (orforglipron)Says NAION has been reported with GLP-1 medicines, and gives no frequency.10 August 2026

    Not being listed does not mean Mounjaro has been shown to be different: the UK review so far covered semaglutide only.

    The MHRA said in its Drug Safety Update of February 2026 that it is "reviewing any evidence for an association with other GLP-1 agonists".

    As of 11 November 2026 the MHRA has not announced a change for Mounjaro.

    Does Mounjaro affect your eyesight in other ways?

    Mounjaro's UK product information lists no eye side effect. Its one eye warning is for people who already have diabetic retinopathy, an eye condition caused by diabetes.

    It says a rapid improvement in blood sugar control "has been associated with a temporary worsening of diabetic retinopathy", and that people who have it should be monitored closely. Its leaflet asks you to tell your doctor, pharmacist or nurse before you start if you have diabetic retinopathy or macular oedema.

    Blurred vision is not a listed side effect either. The NHS lists it as a symptom of both high and low blood sugar, so with diabetes a change in eyesight can go with a change in blood sugar.

    The NHS page on tirzepatide lists vision problems among the signs of low blood sugar, which is more likely if you also take other diabetes medicines. It says not to drive, cycle or use machinery until they pass. Our guide to Mounjaro and type 2 diabetes covers that side of treatment.

    SymptomWhat the UK sources sayWhat to do
    Blurred visionNot listed for Mounjaro. A symptom of high and of low blood sugar (NHS).Eye casualty or A&E if it comes on suddenly in one eye or gets worse very quickly. Otherwise an urgent GP appointment or NHS 111. An optician if your sight is getting worse gradually.
    Diabetic retinopathy getting worseCan get worse for a time when blood sugar improves quickly (Mounjaro product information).Tell your diabetes team before you start, and go to every eye screening appointment.
    Floaters or flashesNot listed for Mounjaro. Common and not usually serious; floaters can be a later symptom of diabetic retinopathy (NHS).An urgent opticians appointment or NHS 111 if they are new, come on suddenly, suddenly increase, or come with blurred vision or eye pain.
    Dry eyes or eye painNot listed for Mounjaro.A pharmacist may be able to help with dry eyes. A painful red eye, or a dark shadow moving across your vision, needs an urgent GP appointment or NHS 111. Sudden severe eye pain, or a red eye with a severe headache and feeling sick, needs A&E or 999.

    What should you do if your vision changes on Mounjaro?

    It depends on how the change came on. A sudden loss of vision, or eyesight getting worse very quickly, is a same-day matter whichever medicine you take.

    1. A sudden loss of vision, or eyesight getting worse very quickly: eye casualty or A&E. If you suddenly cannot see from one or both eyes, lose part of your field of vision, or your eyesight gets worse very quickly, stop your treatment and go to eye casualty, where there is one in your area, or A&E. Sudden severe eye pain needs A&E too. Do not drive: ask someone to take you or call 999, and bring your medicines.

    2. Blurred or double vision, flashes, a shadow or eye pain: an urgent GP appointment or NHS 111. The NHS asks for urgent help for changes such as blurred or double vision, flashing lights or shapes, a dark shadow moving across your vision, or a painful eye. If blurring comes on suddenly in one eye or is getting worse quickly, treat it as step 1.

    3. A gradual change: an optician, or your diabetes team. The NHS says to see an optician if you think you may have vision loss. With diabetes, eyesight getting worse over time or difficulty seeing in low light can also go to your GP or diabetes care team. If you take Wegovy, its leaflet says to contact your doctor urgently if your eyesight gets worse, suddenly or gradually.

    4. Say what you take, then tell your pharmacist. Tell whoever examines you that you take Mounjaro and when your last dose was: the MHRA warns that a privately prescribed GLP-1 medicine may not be on your medical record. Then message your pharmacist before your next dose.

    Should you stop taking Mounjaro because of the FDA warning?

    The FDA has not told people to stop treatment because of the warning. Its advice is to know the symptoms and to contact a healthcare professional straight away if you notice them.

    For anyone who develops NAION, it tells prescribers to consider stopping the medicine unless the benefits clearly outweigh the risk. In the UK, semaglutide is stopped if NAION is confirmed.

    It adds that anyone who has had NAION before should talk to their prescriber about whether to continue, because the risk of it happening again is higher.

    The NHS says to talk to your doctor if you want to stop using tirzepatide, and not to stop suddenly. If you have type 2 diabetes, stopping could affect your blood sugar.

    The exception is a sudden loss of vision, or of part of your field of vision: stop your treatment and get help the same day.

    Not started treatment yet? Check whether it's suitable for you in a few minutes. A GPhC-registered pharmacist reviews every assessment, and if they can't approve your order, you get a full refund.

    Check your eligibility

    What does Solira ask about your eyes?

    Our consultation asks whether you have an eye condition before anything is supplied: glaucoma, diabetic retinopathy, macular degeneration or any other.

    We do not start treatment through our service for anyone with proliferative diabetic retinopathy, which needs a diabetes team or GP first. Any other eye condition is marked for your pharmacist to review.

    If you have ever had NAION, choose "Yes, other eye condition" so your pharmacist can review it.

    The warning sign in this guide was already in the urgent advice every Solira weight-loss patient receives, on Mounjaro and on Wegovy: a sudden loss of vision, or of part of your field of vision, needs a same-day eye assessment.

    Already a Solira patient? If you have ever had NAION, or you are told you have it, tell your pharmacist before your next dose so your treatment can be reviewed. If an optician or your diabetes team says your eyes have changed, message your pharmacist through your account before your next order. If the change was sudden, get medical help first.

    You can report any suspected side effect, eye problems included, to the MHRA through the Yellow Card scheme.

    More on safety: Is Mounjaro safe?, Mounjaro side effects, Is Wegovy safe? and the side effects of each medicine side by side. Our weight loss treatments and safety page have the rest.

    Switching from another provider?

    You may be able to carry on at your current dose. Upload proof of your current treatment during your consultation, and your pharmacist checks it before anything is supplied.

    When should you get help?

    Stop your treatment and seek urgent medical help if you experience: severe, persistent stomach pain, especially spreading to your back, with or without vomiting. This can be a sign of pancreatitis. Sudden pain in the upper right of your tummy, fever, or yellowing of the skin or eyes: possible gallbladder problems. Sudden loss of vision, or loss of part of your field of vision: seek same-day eye assessment. Swelling of the face or lips, difficulty breathing, or a widespread rash: call 999.

    Seek advice promptly if you notice: signs of dehydration during vomiting or diarrhoea (dizziness, reduced urination, dry mouth): keep sipping fluids, as dehydration can affect your kidneys; palpitations or a racing heartbeat at rest; a new neck lump, swelling, or hoarseness. If you have type 2 diabetes and use insulin or a sulfonylurea, know the signs of low blood sugar (sweating, shaking, sudden hunger, confusion) and treat promptly.

    Before any operation: tell your surgical or anaesthetic team you take a GLP-1 medicine. It slows stomach emptying, which matters for anaesthesia.

    If your eyesight gets worse very quickly, in one eye or both, go to eye casualty, where there is one in your area, or A&E. Sudden severe eye pain needs A&E or 999.

    If you have diabetes and get blurred vision that is not sudden, ask for an urgent GP appointment or get help from NHS 111.

    Tell whoever examines your eyes which GLP-1 medicine you take and when your last dose was. Messages to your pharmacist are not for emergencies: see what to do if it's urgent.

    For urgent medical concerns, call NHS 111 or 999.

    Urgent help, genuine medicines and the official leaflets

    Frequently asked questions

    The UK product information for Mounjaro (tirzepatide), text revised August 2026, lists no eye side effect, and its one eye warning is for people who already have diabetic retinopathy. On 9 November 2026 the US regulator, the FDA, told the makers of every GLP-1 medicine, Mounjaro included, to add a warning about NAION, a rare condition that causes a sudden, painless loss of vision, usually in one eye. In the FDA's analysis of 126 trials there were 6.4 cases a year for every 100,000 people on a GLP-1 medicine and 3.8 for every 100,000 on a placebo or another diabetes medicine. A sudden loss of vision, or of part of your field of vision, needs eye casualty or A&E the same day.

    It is not known for certain, and if it can, it is rare. NAION, the eye condition in the FDA's November 2026 warning, can cause permanent loss of vision, usually in one eye. The FDA describes a potential increased risk of it with GLP-1 medicines as a group and says cases have been reported with every GLP-1 medicine on the market; its review of animal studies did not identify how one could lead to it. Blindness is not listed as a side effect in Mounjaro's UK product information, text revised August 2026. If you suddenly lose vision, or part of your field of vision, stop your treatment and go to eye casualty or A&E the same day.

    On 9 November 2026 the FDA said it is requiring the makers of all GLP-1 medicines to add information about a potential increased risk of NAION to the Warnings and Precautions section of their US prescribing information. Its list includes Mounjaro and Zepbound (tirzepatide), Wegovy, Ozempic and Rybelsus (semaglutide) and Foundayo (orforglipron). The notice does not describe it as a boxed warning, and it does not tell people to stop treatment because of the warning. For anyone who develops NAION, it tells prescribers to consider stopping the medicine unless the benefits clearly outweigh the risk.

    Not directly. The FDA regulates medicines in the United States; in the UK that is the MHRA. In February 2026 the MHRA warned that semaglutide (Wegovy, Ozempic and Rybelsus) may very rarely be linked to NAION, and said it is reviewing the evidence for other GLP-1 medicines. As of 11 November 2026, NAION is not listed in the UK product information for Mounjaro, and the MHRA has not announced a change. That does not mean Mounjaro has been shown to be different: the UK review so far covered semaglutide only. The advice is the same either way: a sudden loss of vision needs eye casualty or A&E the same day.

    The FDA lists a sudden, painless loss of vision in one eye, which may be noticed on waking; blurred or missing parts of your vision, such as blind spots or tunnel vision; colours looking distorted; and blurry or hazy central vision. The MHRA says it is often described as a blurring or cloudiness of vision, usually in one eye. For a sudden loss of vision, or of part of your field of vision, blurring that comes on suddenly in one eye, or eyesight that gets worse very quickly, stop your treatment and go to eye casualty, where there is one in your area, or A&E. Do not drive yourself. For any other change, contact a healthcare professional straight away: ask for an urgent GP appointment or call NHS 111.

    Blurred vision is not listed as a side effect in Mounjaro's UK product information. The NHS lists blurred vision as a symptom of both high and low blood sugar, and its page on tirzepatide lists vision problems among the signs of low blood sugar, which is more likely if you also take other diabetes medicines. Blurring that comes on suddenly in one eye, or gets worse very quickly, can also be a sign of NAION and needs eye casualty or A&E the same day. For other blurred vision, the NHS says to ask for an urgent GP appointment or get help from NHS 111.

    The FDA has not told people to stop treatment because of the warning. Its advice is to know the symptoms of NAION and to contact a healthcare professional straight away if they appear, and it says anyone who has had NAION before should talk to their prescriber about whether to continue. The NHS says to talk to your doctor if you want to stop using tirzepatide, and not to stop suddenly; if you have type 2 diabetes, stopping could affect your blood sugar. The exception is a sudden loss of vision, or of part of your field of vision: stop your treatment and go to eye casualty or A&E the same day.

    It is not known. Most of the research is on semaglutide (Wegovy and Ozempic) in people with type 2 diabetes, and the European Medicines Agency and the MHRA list NAION as a very rare side effect of semaglutide, affecting up to 1 in 10,000 people. There is much less research on tirzepatide (Mounjaro), and none of it can show whether the risk differs between medicines. The FDA says cases have been reported with every GLP-1 medicine on the market and applied its warning to all of them, so the same warning signs apply whichever you take.

    The UK product information does not rule it out: it says a rapid improvement in blood sugar control has been linked to a temporary worsening of diabetic retinopathy, so people who have it should be monitored closely. Our own rule is stricter for one type. We do not start treatment through our service if you have proliferative diabetic retinopathy, which needs your diabetes team or GP first. Mild or non-proliferative retinopathy does not stop the consultation: your order is marked for your pharmacist to review, and we recommend telling your eye specialist and keeping your regular eye appointments.

    It depends on the cause, so have it checked instead of waiting to see. Mounjaro's UK product information describes the worsening of diabetic retinopathy that can follow a fast improvement in blood sugar as temporary. The loss of vision from NAION can be permanent, the FDA says, which is why a sudden change needs eye casualty or A&E the same day. Tell whoever examines your eyes that you take Mounjaro and when your last dose was.

    Keep reading

    Sources · 27Show
    1. US Food and Drug Administration. FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition. Drug Safety Communication, 9 November 2026.
    2. MHRA Drug Safety Update. Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION). 5 February 2026.
    3. MHRA. GLP-1 medicines for weight loss and diabetes: what you need to know. Updated 5 February 2026.
    4. MHRA Drug Safety Update. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases. 29 January 2026.
    5. European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. 6 June 2025.
    6. Mounjaro KwikPen Summary of Product Characteristics, sections 4.4 and 4.8, electronic medicines compendium. Text revised 29 August 2026.
    7. Mounjaro KwikPen patient information leaflet, section 2, electronic medicines compendium. Last revised August 2026.
    8. Wegovy FlexTouch Summary of Product Characteristics, sections 4.4 and 4.8, electronic medicines compendium. Revised September 2026.
    9. Wegovy FlexTouch patient information leaflet, sections 2 and 4, electronic medicines compendium. Last revised August 2026.
    10. Wegovy tablets Summary of Product Characteristics, sections 4.4 and 4.8, electronic medicines compendium. Revised June 2026.
    11. Foundayo Summary of Product Characteristics, section 4.8, electronic medicines compendium. Text revised 10 August 2026.
    12. NHS. Vision loss. Page last reviewed 28 August 2025.
    13. NHS. Diabetic retinopathy. Page last reviewed 17 July 2025.
    14. NHS. High blood sugar (hyperglycaemia). Page last reviewed 17 March 2026.
    15. NHS. Low blood sugar (hypoglycaemia). Page last reviewed 3 August 2023.
    16. NHS. Tirzepatide. Page last reviewed 15 May 2026.
    17. NHS. Floaters and flashes in the eyes. Page last reviewed 20 June 2023.
    18. NHS. Dry eyes. Page last reviewed 6 January 2025.
    19. Hathaway JT et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol 2024;142(8):732-739. doi:10.1001/jamaophthalmol.2024.2296.
    20. Grauslund J et al. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous 2024;10(1):97. doi:10.1186/s40942-024-00620-x.
    21. Simonsen E et al. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study. Diabetes Obes Metab 2025;27(6):3094-3103. doi:10.1111/dom.16316.
    22. Cai CX et al. Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmol 2025;143(4):304-314. doi:10.1001/jamaophthalmol.2024.6555.
    23. Wang L et al. Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes. JAMA Netw Open 2025;8(8):e2526327. doi:10.1001/jamanetworkopen.2025.26327.
    24. Chou CC et al. Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: A Multinational Population-Based Study. Ophthalmology 2025;132(4):381-388. doi:10.1016/j.ophtha.2024.10.030.
    25. Abbass NJ et al. The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy. Am J Ophthalmol 2025;274:24-31. doi:10.1016/j.ajo.2025.02.025.
    26. Kakkar AK et al. Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data. Diabetes Obes Metab 2026;28(8):7527-7535. doi:10.1111/dom.70952.
    27. Hong AT et al. Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes. Ophthalmol Retina 2026;10(6):625-632. doi:10.1016/j.oret.2026.02.002.

    Reviewed by Jimah Alsaai MPharm, GPhC 2232652, Superintendent Pharmacist, QuickCare Pharmacy.

    Ready to start?

    Start your free consultation with a GPhC-registered pharmacist.

    Begin consultation

    Follow us on Instagram (opens Instagram in a new tab)